The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 1062-1067

  Vile, Richard ^a   Ando, Dale ^b   Kirn, David ^c,d  

^a MAYO CLINIC   (United States)

^b CELL GENESYS INC   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Kirn Oncology Consulting   (United States)

Author keywords

Cancer; Experimental therapeutics; Oncolytic; Virotherapy

Indexed keywords

CD20 ANTIGEN; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; ONYX 015; PRODRUG; RITUXIMAB;

ADENOVIRUS; BIOSAFETY; CANCER; CANCER THERAPY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG SAFETY; GENETIC ENGINEERING; GOOD MANUFACTURING PRACTICE; HEAD AND NECK CANCER; HUMAN; MEASLES VIRUS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; POXVIRUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS STRAIN; GENE THERAPY; GENETICS; METHODOLOGY; NEOPLASM; PATHOGENICITY; PRACTICE GUIDELINE; PUBLIC HEALTH; RISK FACTOR; SAFETY; STANDARD; VIROLOGY; VIRUS;

ADENOVIRIDAE; MEASLES VIRUS; POXVIRIDAE; VACCINIA VIRUS;

CLINICAL TRIALS; GENE THERAPY; GUIDELINES; HUMANS; NEOPLASMS; PUBLIC HEALTH; RISK FACTORS; SAFETY; VIRUSES;

EID: 0036903118     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700548     Document Type: Review

References (57)

1. Southam CM. Present status of oncolytic virus studies. Ann NY Acad Sci. 1960:656-673.
2. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-856.
3. Lorence RM, Rood PA, Kelley KW. Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst. 1988;80:1305-1312.
4. Coffey M, Strong J, Forsyth P, Lee P. Reovirus therapy of tumors with activated ras pathway. Science. 1998;282:1332-1334.
5. Stojdl DF, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821-825.
6. Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods. 1991;33:233-251.
7. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-856.
8. Bischoff JR, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science. 1996;274:373-376.
9. Heise C, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nat Med. 1997;3:639-645.
10. Mastrangelo M, Eisenlohr L, Gomella L, Lattime E. Poxvirus vectors: Orphaned and underappreciated. J Clin Invest. 2000;105:1031-1034.
11. Heise C, et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nat Med. 2000;6:1134-1139.
12. Fueyo J, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2-12.
13. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma [see comments]. Proc Natl Acad Sci USA. 2000;97:6803-6808.
14. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997;71:5124-5132.
15. Wickham TJ, Shears TEL, Roelvink P, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 1997;71:8221-8229.
16. Alemany R, Curiel DT. The development of replicative adenoviruses for cancer therapy. Clin Cancer Res. 2000;6:3395-3399.
17. Heise C, Williams A, Olesch J, Kim D. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects. Cancer Gene Ther. 1999;6:499-504.
18. Ganly I, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798-806.
19. Wu JT, Byrne HM, Kim DH, Wein LM. Modeling and analysis of a virus that replicates selectively in tumor cells. Bull Math Biol. 2001;63:731-768.
20. + locus codes for a 19 kD tumor antigen that plays an essential role in cell transformation. Cell. 1983;33:759-766.
21. Sauthoff H, Heitner S, Rom W, Hay J. Deletion of the adenoviral E1B-19 kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther. 2000;11:379-388.
22. Doronin K, et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
23. Shenk T. In: Fields K, Howley P, eds. Fields Virology. Philadelphia: Lippincott-Raven; 1996:2135-2137.
24. Smith GL, Vanderplasschen A. Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv Exp Med Biol. 1998;440:395-414.
25. Douglas J, Kim M, Sumerel L, Carey D, Curiel D. Efficient oncolysis by a replicating adenovirus in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res. 2001;61:813-817.
26. Rauen KA, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res. 2002;62:3812-3818.
27. Vasey P, Shulman L, Gore M, Kim D, Kaye S. Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma. Proc Am Soc Clin Oncol. 2000;19:1512. (Abstract).
28. Nemunaitis J, et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55 kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 2000;60:6359-6366.
29. Mulvihill S, Warren R, Kim D. Safety and feasibility of injection with an E1B-55 kD gene-deleted replication-selective adenovirus Onyx-015 into primary carcinomas of the pancreas: A phase I trial. Gene Ther. 2001;8:308-315.
30. Roelvink P, Mi G, Einfeld D, Kovesdi I, Wickham T. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science. 1999;286:1568-1571.
31. Suzuki K, et al. A replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001;7:120-126.
32. Kim D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 2001;8:89-98.
33. Toda T, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 1999;10:2741-2755.
34. Herrlinger U, et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 1998;5:809-819.
35. Merritt J, et al. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer. Cancer Gene Ther. 1997;4:S12. (Abstract).
36. Reid T, et al. Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: A phase I/II clinical trial. Proc Am Soc Clin Oncol. 2000;19:953. (Abstract).
37. Reid T, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther. 2001;8:1618-1626.
38. Nemunaitis J, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 2001;8:746-759.
39. Pecora AL, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20:2251-2266.
40. Kim D. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer. Oncogene. 2000;1:6660-6668.
41. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA. 1998;95:7544-7549.
42. Heise C, Williams A, Xue S, Propst M, Kim D. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999;59:2623-2628.
43. Ikeda K, Chiocca N. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited anti-viral responses. Nat Med. 1999;5:881-887.
44. Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 1999;59:3396-3403.
45. Gnant MF, et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst. 1999;91:1744-1750.
46. Kirn D, Warren R. Liver-directed therapy with p53-targeted adenoviruses: Clinical trial results. Surg Clin North Am. 2002. (In press).
47. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
48. Markert J, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 2000;7:867-874.
49. Hermiston T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169-1172.
50. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998;160:4457-4464.
51. Wildner O, Blaese RM, Morris JM. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999;59:410-413.
52. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy [see comments]. Hum Gene Ther. 1998;9:1323-1333.
53. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest. 2000;106:763-771.
54. Russell SJ. Gene therapy for cancer. Lancet. 1992;339:1109-1110.
55. Haag A, et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther. 2000;11:597-609.
56. McCart JA, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 2000;7:1217-1223.
57. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.